• Emmanuelle Billon-Denis and Jean-Nicolas Tournier.
• Institut de recherche biomédicale des armées (IRBA), Unité biothérapies anti-infectieuses et immunité, 1 place Général Valérie André, 91220 Brétigny-sur-Orge, France - Institut Pasteur, Innovative vaccine laboratory, 75015 Paris, France.
• Med Sci (Paris). 2020 Nov 1; 36 (11): 1034-1037.

AbstractCoronavirus disease (COVID)-19 is an emerging pandemic infection whose significant ability to spread in a naïve population is well established. The first response of states to the COVID-19 outbreak was to impose lock-down and social barrier measures, such as wearing a surgical mask or social distancing. One of the consequences of this pandemic in terms of public health was the suspension or slowdown of infant vaccination campaigns, in almost all countries. The indirect effects of COVID-19 may therefore weigh on mortality from measles and polio in developing countries. In this pandemic chaos, the only hope lies in the rapid development of an effective vaccine against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). However, acceptance of this vaccine has not yet been won, as beyond the many unknowns that will inevitably weigh around such rapid development, skepticism among vaccine hesitants is growing.© 2020 médecine/sciences – Inserm.

43 keywords...

hide…